Ipragliflozin/ja: Difference between revisions
Ipragliflozin/ja
Created page with "<!-- Clinical data --> | tradename = Suglat | Drugs.com = | MedlinePlus = | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | pregnancy_AU_comment = | pregnancy_US = <!-- A / B / C / D / X / N --> | pregnancy_category = | legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> | legal_AU_comment = | legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> | legal_NZ = <!--Class A, B, C --> | legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM..." Tags: Mobile edit Mobile web edit |
Created page with "<!-- Pharmacokinetic data --> | bioavailability = 90.2% | protein_bound = 94.6–96.5% | metabolism = UGT2B7/ja (major), UGT2B4/ja, 1A8, 1A9 (minor) | metabolites = | onset = | elimination_half-life = 14.97±4.58 hours | duration_of_action = | excretion = Urine/ja (67.9%), feces/ja (32.7%)" Tags: Mobile edit Mobile web edit |
||
| Line 51: | Line 51: | ||
| synonyms = (1''S'')-1,5-anhydro-1-''C''-{3-[(1-benzothiophen-2-yl)methyl]-4-fluorophenyl}-<small>D</small>-glucitol | | synonyms = (1''S'')-1,5-anhydro-1-''C''-{3-[(1-benzothiophen-2-yl)methyl]-4-fluorophenyl}-<small>D</small>-glucitol | ||
<!-- Chemical data --> | <!-- Chemical data --> | ||
| chemical_formula = | | chemical_formula = | ||
| Line 59: | Line 58: | ||
| StdInChIKey = AHFWIQIYAXSLBA-RQXATKFSSA-N | | StdInChIKey = AHFWIQIYAXSLBA-RQXATKFSSA-N | ||
}} | }} | ||
<div lang="en" dir="ltr" class="mw-content-ltr"> | <div lang="en" dir="ltr" class="mw-content-ltr"> | ||